Luncheon Panel: Prescription Drug Prices
May 23, 2016
12:00–1:45 pm
The shifting sands of competition and innovation are evident across the industry—innovators, generics, small molecule and biologics—and drug prices are, once again, front line news and a target for policy makers and litigation.
Our panel will bring together top minds from the legal, regulatory, and commercial communities to shed light on:
- How economic forces can drive prices for branded and generic drugs
- How government agencies, such as the FDA and CMS, can wield their policy making abilities to influence drug markets and prices
- How litigation will be used in addressing drug prices
- What the future holds for both legislative and regulatory initiatives aimed at drug pricing
Panelists include:
- Tamer Abdelgawad, MA—Senior Director of International Policy, Pfizer
- Jim Cohen, JD—Former FDA senior legal advisor
- Allan Coukell, BScPharm—Senior Director of Health Programs, Pew Charitable Trusts
- Jim Stansel, JD—Partner, Sidley Austin
- Anne Wilson, MBA—Head of North America Policy, Mylan
- Chris Stomberg, PhD—Partner, Bates White (moderator)
Location
Willard InterContinental (Crystal Room)
1401 Pennsylvania Avenue, NW
Washington, DC 20004
Registration
11:30–12:00 p.m.
Panel and lunch
12:00–1:45 p.m.
Registration is complimentary. If you are interested in attending, please email Ngar Eldredge.
